MCID: ART008
MIFTS: 42

Arteriosclerosis Obliterans

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

MalaCards integrated aliases for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 52 42 14 69
Arteriosclerosis Obliterans [ambiguous] 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
MeSH 42 D001162
SNOMED-CT 64 361133006 60625000
UMLS 69 C0003851

Summaries for Arteriosclerosis Obliterans

MalaCards based summary : Arteriosclerosis Obliterans, also known as arteriosclerosis obliterans [ambiguous], is related to ischemic heart disease and myocardial infarction. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are Cytokine Signaling in Immune system and HTLV-I infection. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and bone marrow, and related phenotypes are cardiovascular system and cellular

Wikipedia : 72 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
id Related Disease Score Top Affiliating Genes
1 ischemic heart disease 30.4 IL6 SELP
2 myocardial infarction 29.5 ADIPOQ ICAM1 IL6 SELP
3 peripheral artery disease 29.0 ADIPOQ ICAM1 IL6 SELP VCAM1
4 systemic lupus erythematosus 28.5 ICAM1 IL18 IL6 VCAM1
5 arteriosclerosis 10.9
6 parasitic helminthiasis infectious disease 10.5 IL6 SELP
7 hyperlipoproteinemia type iv 10.5 ADIPOQ IL6
8 lymphomatous thyroiditis 10.5 ICAM1 VCAM1
9 heart lymphoma 10.4 ICAM1 VCAM1
10 marginal corneal ulcer 10.4 ICAM1 VCAM1
11 neuroaxonal dystrophy 10.4 ICAM1 IL6
12 hyperaldosteronism 10.4 ICAM1 IL6
13 inferolateral myocardial infarct 10.4 ICAM1 VCAM1
14 moved to 244450 10.4 ICAM1 VCAM1
15 cutaneous leishmaniasis 10.4 HGF IL6
16 riboflavin transporter deficiency 10.4 ICAM1 VCAM1
17 liver disease 10.4 ICAM1 VCAM1
18 ovarian mucinous adenofibroma 10.4 IL6 VCAM1
19 dislocation of ear ossicle 10.4 ICAM1 VCAM1
20 corpus callosum agenesis of blepharophimosis robin type 10.4 ADIPOQ VCAM1
21 lichen planus 10.4 ICAM1 IL6
22 phlegmonous dacryocystitis 10.4 ICAM1 VCAM1
23 craniopharyngioma 10.4 ICAM1 VCAM1
24 conduct disorder 10.4 ICAM1 IL6
25 nodular prostate 10.4 ICAM1 IL6
26 benign secondary hypertension 10.3 ICAM1 VCAM1
27 dentin dysplasia 10.2 ICAM1 VCAM1
28 focal dystonia 10.2 IL6 SELP VCAM1
29 orbital melanoma 10.2 ICAM1 VCAM1
30 angina pectoris 10.2 IL6 SELP VCAM1
31 pericarditis 10.2 ADIPOQ SELP VCAM1
32 proximal symphalangism 10.2 ICAM1 VCAM1
33 angiokeratoma 10.2 ICAM1 SELP VCAM1
34 oppositional defiant disorder 10.2 ICAM1 SELP VCAM1
35 psychosexual disorder 10.2 ICAM1 SELP VCAM1
36 periampullary adenoma 10.2 ADIPOQ ICAM1 IL6
37 intra-abdominal lymph node mast cell malignancy 10.1 ICAM1 SELP VCAM1
38 aneurysm 10.1
39 macular degeneration, age-related, 12 10.1 ADIPOQ IL6 SELP
40 x-linked dominant intellectual disability-epilepsy syndrome 10.1 IL18 IL6
41 dysphagia 10.1 ICAM1 IL6 VCAM1
42 heart disease 10.1
43 stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features 10.1 IL18 IL6
44 hyperpigmentation of eyelid 10.1 ICAM1 IL6 VCAM1
45 orthostatic proteinuria 10.1 IL18 IL6
46 chronic myelomonocytic leukemia 10.1 ICAM1 IL6 VCAM1
47 syphilitic encephalitis 10.1 IL18 IL6
48 advanced sleep phase syndrome, familial, 1 10.1 ICAM1 IL6 VCAM1
49 ischemia 10.1
50 aortic aneurysm 10.1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 VCAM1 ADIPOQ HGF ICAM1 IL18 IL6
2 cellular MP:0005384 9.7 ADIPOQ HGF ICAM1 IL18 IL6 SELP
3 growth/size/body region MP:0005378 9.5 ADIPOQ HGF ICAM1 IL18 IL6 SELP
4 hematopoietic system MP:0005397 9.17 ADIPOQ HGF ICAM1 IL18 IL6 SELP

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved Phase 4 73963-72-1 2754
3
Probucol Approved Phase 4 23288-49-5 4912
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Remifentanil Approved Phase 4 132875-61-7 60815
7
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
8
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
9 Analgesics Phase 4
10 Analgesics, Non-Narcotic Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Anti-Inflammatory Agents Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Antipyretics Phase 4
15 Antirheumatic Agents Phase 4
16 Autonomic Agents Phase 4
17 Bronchodilator Agents Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19 Fibrinolytic Agents Phase 4
20 Neuroprotective Agents Phase 4
21 Peripheral Nervous System Agents Phase 4
22 Phosphodiesterase 3 Inhibitors Phase 4
23 Phosphodiesterase Inhibitors Phase 4
24 Platelet Aggregation Inhibitors Phase 4,Phase 2
25 Protective Agents Phase 4
26 Respiratory System Agents Phase 4
27 Vasodilator Agents Phase 4,Phase 2
28 Anticholesteremic Agents Phase 4
29 Antimetabolites Phase 4
30 Antioxidants Phase 4
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Angiotensin Receptor Antagonists Phase 4
35 Angiotensin-Converting Enzyme Inhibitors Phase 4
36 Angiotensinogen Phase 4
37 Antihypertensive Agents Phase 4
38 diuretics Phase 4
39 Natriuretic Agents Phase 4
40 Sodium Chloride Symporter Inhibitors Phase 4
41 Analgesics, Opioid Phase 4
42 Anesthetics Phase 4,Phase 1,Phase 2
43 Anesthetics, General Phase 4
44 Anesthetics, Inhalation Phase 4
45 Anesthetics, Intravenous Phase 4
46 Central Nervous System Depressants Phase 4
47 Hypnotics and Sedatives Phase 4
48 Narcotics Phase 4
49
Alprostadil Approved, Investigational Phase 2 745-65-3 149351
50 Anticoagulants Phase 2

Interventional clinical trials:

(show all 14)

id Name Status NCT ID Phase Drugs
1 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4 cilostazol
2 Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
3 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
4 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
5 Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Recruiting NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
6 TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Unknown status NCT00145262 Phase 2
7 Autologous Bone Marrow For Lower Extremity Ischemia Treating Completed NCT00753025 Phase 2
8 A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans Recruiting NCT02877173 Phase 2 Alprostadil Liposomes for Injection;Alprostadil Injection
9 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Enrolling by invitation NCT02864654 Phase 1, Phase 2
10 Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Not yet recruiting NCT02501018 Phase 2 SOC
11 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
12 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F) Completed NCT01518205
13 ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease Completed NCT01064206
14 Arterial Calcification in the Diabetes Active, not recruiting NCT02431234

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

39
Heart, Bone, Bone Marrow, Smooth Muscle, Skin, Endothelial, T Cells

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 243)
id Title Authors Year
1
Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans. ( 28848136 )
2017
2
The Association between Polymorphism of CARD8 rs2043211 and Susceptibility to Arteriosclerosis Obliterans in Chinese Han Male Population. ( 28135700 )
2017
3
A Rare Complication of Spinal Cord Ischemia Following Endovascular Aneurysm Repair of an Infrarenal Abdominal Aortic Aneurysm with Arteriosclerosis Obliterans: Report of a Case. ( 27738476 )
2016
4
Emerging Novel Biomarkers for Arteriosclerosis Obliterans. ( 26632166 )
2016
5
Baseline Characterization of Japanese Peripheral Arterial Disease Patientsa88- Analysis of Surveillance of Cardiovascular Events in Antiplatelet-Treated Arteriosclerosis Obliterans Patients in Japan (SEASON). ( 26841805 )
2016
6
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. ( 25959199 )
2015
7
MicroRNA-133a in the Development of Arteriosclerosis Obliterans. ( 25740337 )
2015
8
Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. ( 26370316 )
2015
9
Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. ( 26159387 )
2015
10
Logistic Regression Analysis of Depression in Arteriosclerosis Obliterans Patients and Its Risk Factors. ( 26564507 )
2015
11
MiR-142-3p attenuates the migration of CD4a8_ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. ( 24743945 )
2014
12
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. ( 25445891 )
2014
13
Relationship between Arteriosclerosis Obliterans and the Ratio of Serum Eicosapentaenoic Acid to Arachidonic Acid. ( 23364231 )
2013
14
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( 23364237 )
2013
15
Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. ( 23749750 )
2013
16
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. ( 22259111 )
2012
17
A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. ( 23097651 )
2012
18
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. ( 23065872 )
2012
19
MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. ( 21817107 )
2011
20
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). ( 20966606 )
2010
21
Current status of the medical expenses for the treatment of arteriosclerosis obliterans in Japan. ( 20357751 )
2010
22
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. ( 20357749 )
2010
23
Characteristics of revascularization treatment for arteriosclerosis obliterans in patients with and without hemodialysis. ( 20938099 )
2010
24
[Evaluation of proinflammatory cytokines in chronic lower limb ischaemia diabetic macroangiopathy and arteriosclerosis obliterans]. ( 20120706 )
2009
25
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. ( 19225945 )
2009
26
Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans. ( 18175063 )
2008
27
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. ( 18270875 )
2008
28
Detecting vulnerable plaque of arteriosclerosis obliterans by multidetector-row computed tomography--comparing with VH (virtual histology)-intravascular ultrasound. ( 17512620 )
2008
29
Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). ( 18724029 )
2008
30
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. ( 18375400 )
2008
31
Intractable wounds caused by arteriosclerosis obliterans with end-stage renal disease treated by aggressive debridement and epidermal grafting. ( 17637445 )
2007
32
Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. ( 17652880 )
2007
33
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. ( 17126824 )
2007
34
Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. ( 17610290 )
2007
35
Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. ( 18064333 )
2007
36
Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. ( 17186986 )
2007
37
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. ( 17249520 )
2006
38
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. ( 16763534 )
2006
39
Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. ( 16865304 )
2006
40
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. ( 15877296 )
2005
41
Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. ( 15488869 )
2004
42
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. ( 15203718 )
2004
43
The effect of Liple on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. ( 15765038 )
2004
44
Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. ( 15564705 )
2004
45
Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. ( 15080020 )
2004
46
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. ( 15372302 )
2004
47
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. ( 15224807 )
2004
48
Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. ( 14983238 )
2004
49
Estimating the stenosis probabilities in arteriosclerosis obliterans using generalized estimating equations. ( 12820280 )
2003
50
Peripheral macrohemodynamics in patients with lower limb arteriosclerosis obliterans and type II diabetes mellitus. ( 12811388 )
2003

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

Pathways related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 HGF ICAM1 IL18 IL6 VCAM1
2 12.19 ICAM1 IL6 VCAM1
3 11.89 ICAM1 SELP VCAM1
4 11.83 HGF IL6 VCAM1
5 11.77 ICAM1 IL6 SELP
6 11.7 ICAM1 IL6 VCAM1
7 11.65 ICAM1 IL6 VCAM1
8 11.62 ADIPOQ IL6 VCAM1
9 11.56 ICAM1 IL18 IL6
10 11.43 ICAM1 IL6 VCAM1
11 11.41 HGF ICAM1 IL18 IL6 VCAM1
12
Show member pathways
11.34 ICAM1 IL6 VCAM1
13 11.31 HGF IL6
14 11.28 ICAM1 VCAM1
15 11.26 ICAM1 VCAM1
16 11.22 CARD8 IL18
17 11.19 ICAM1 IL18 IL6
18 11.11 ICAM1 IL6 SELP
19 11.1 IL18 IL6
20 11 ICAM1 IL18 IL6 VCAM1
21 10.98 ICAM1 IL18
22 10.98 HGF IL18 IL6
23 10.91 IL18 VCAM1
24 10.9 ADIPOQ IL6
25 10.79 HGF ICAM1 IL18 IL6 SELP VCAM1
26 10.74 ICAM1 VCAM1

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 IL6 SELP VCAM1
2 extracellular space GO:0005615 9.17 ADIPOQ HGF ICAM1 IL18 IL6 SELP

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.76 ADIPOQ ICAM1 VCAM1
2 regulation of cell shape GO:0008360 9.73 ICAM1 IL6 TPM1
3 cellular response to tumor necrosis factor GO:0071356 9.67 ICAM1 IL6 VCAM1
4 response to ethanol GO:0045471 9.65 ADIPOQ ICAM1 VCAM1
5 negative regulation of fat cell differentiation GO:0045599 9.63 ADIPOQ IL6
6 regulation of cell adhesion GO:0030155 9.62 ICAM1 IL18
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 ICAM1 IL6
8 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.61 ADIPOQ CARD8
9 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.61 HGF ICAM1
10 cellular response to dexamethasone stimulus GO:0071549 9.6 ICAM1 IL6
11 response to amino acid GO:0043200 9.59 ICAM1 IL6
12 calcium-mediated signaling using intracellular calcium source GO:0035584 9.58 SELP VCAM1
13 leukocyte tethering or rolling GO:0050901 9.55 SELP VCAM1
14 negative regulation of gluconeogenesis GO:0045721 9.54 ADIPOQ IL6
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.54 HGF IL18 SELP
16 cellular response to hepatocyte growth factor stimulus GO:0035729 9.52 HGF IL6
17 acute inflammatory response GO:0002526 9.51 IL6 VCAM1
18 cellular response to nutrient levels GO:0031669 9.46 ICAM1 IL6
19 response to lipopolysaccharide GO:0032496 9.46 ICAM1 IL6 SELP VCAM1
20 negative regulation of hormone secretion GO:0046888 9.43 ADIPOQ IL6
21 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.43 ICAM1 SELP VCAM1
22 positive regulation of T-helper 2 cell differentiation GO:0045630 9.4 IL18 IL6
23 membrane to membrane docking GO:0022614 9.32 ICAM1 VCAM1
24 negative regulation of tumor necrosis factor-mediated signaling pathway GO:0010804 9.27 ADIPOQ
25 leukocyte cell-cell adhesion GO:0007159 9.13 ICAM1 SELP VCAM1
26 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 8.92 ADIPOQ HGF ICAM1 IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 ADIPOQ IL18 IL6
2 sialic acid binding GO:0033691 8.62 ADIPOQ SELP

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....